U.S. Stocks Rise Amid U.S.-Iran Negotiations and Strong Job Gains
Wall St ends higher as investors parse US-Iran negotiations, threats
Mint
Image: Mint
U.S. stocks closed higher as investors reacted to ongoing U.S.-Iran ceasefire negotiations and a positive jobs report showing 178,000 jobs added in March. Despite threats from President Donald Trump, market optimism remains as the S&P 500 and Nasdaq mark their fourth consecutive day of gains.
- 01U.S. stocks advanced as investors sought clarity on U.S.-Iran negotiations.
- 02March jobs report revealed 178,000 jobs added, significantly surpassing expectations.
- 03Despite gains, the S&P 500 is still down about 4% since the onset of the U.S.-Iran conflict.
- 04Inflation fears persist as prices paid in the services sector hit a 3.5-year high.
- 05Soleno Therapeutics shares surged following a $2.9 billion acquisition by Neurocrine Biosciences.
Advertisement
In-Article Ad
U.S. stocks rose on April 6, 2023, as investors focused on the potential for a ceasefire between the U.S. and Iran amid escalating tensions. President Donald Trump's threats regarding the Strait of Hormuz have heightened market volatility. The S&P 500 gained 29.02 points (0.44%) to close at 6,611.71 points, while the Nasdaq Composite rose 114.29 points (0.52%) to 21,993.47 points. The Dow Jones Industrial Average also increased by 170.36 points (0.37%) to 46,675.03. The March jobs report showed the U.S. economy added 178,000 jobs, nearly tripling the expected 60,000, although previous job losses were revised upward. Despite this positive news, the S&P 500 remains down about 4% since the conflict began, as inflation fears continue to loom due to rising prices in the services sector, which reached a 3.5-year high. Additionally, shares of Soleno Therapeutics surged following the announcement of a $2.9 billion acquisition by Neurocrine Biosciences.
Advertisement
In-Article Ad
The strong job growth indicates a recovering job market, which can lead to increased consumer spending and economic stability.
Advertisement
In-Article Ad
Reader Poll
Do you think the U.S. economy will continue to grow in the coming months?
Connecting to poll...
More about Neurocrine Biosciences
Oppenheimer abaisse la note de Soleno Therapeutics suite à l'acquisition par Neurocrine Biosciences
Investing French • Apr 7, 2026
Oppenheimer reduce la calificación de Soleno Therapeutics tras adquisición por Neurocrine Biosciences
Investing • Apr 7, 2026
Wall Street schließt im Plus trotz geopolitischer Unsicherheiten
Ntv • Apr 7, 2026
Read the original article
Visit the source for the complete story.